He currently serves as the senior vice president of research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.
Manning is responsible for research and the discovery of novel products as the senior vice president of research at Momenta Pharmaceuticals, Inc.
Since joining Momenta, his team has advanced three novel autoimmune drugs into development.
Prior to Momenta, Manning was vice president and head of immunology research for Biogen Idec, Inc.
Before that, he was vice president and global head of inflammation, autoimmunity and transplantation research at Roche Pharmaceuticals.
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins